Irvine–Gass Syndrome

Pathophysiology
Types
Causes and Risk Factors
Symptoms
Diagnostic Tests
Non-pharmacological treatments
Drug treatments
Dietary molecular supplements
Regenerative / stem-cell” options
Surgeries
Preventions
When to see a doctor (or go urgently)
Foods to favor — and to limit/avoid
Frequently asked questions

Irvine–Gass Syndrome is swelling in the center of the retina (the macula) that happens after cataract surgery. The swelling forms many tiny fluid-filled spaces shaped like small cysts. Doctors call that pattern “cystoid macular edema.” The macula controls sharp, detailed, central vision, so swelling here usually makes vision blurry or distorted. Most cases start a few weeks after surgery. Many cases get better on their own over months, but some last longer and need treatment. The condition is common enough that eye doctors look for it routinely after cataract surgery. EyeWiki

Irvine–Gass syndrome is swelling in the center of the retina (the macula) that can appear after cataract surgery. Many tiny blood vessels in the retina normally keep fluid inside by using a “blood-retinal barrier.” During and after surgery, inflammation chemicals (like prostaglandins and other cytokines) can loosen this barrier. Fluid then seeps into the macula and forms small fluid pockets (“cysts”), which blur or warp central vision. Most cases are mild and improve on their own, but some cases last for months and need treatment to protect vision. PMCReview of Ophthalmology

With modern cataract surgery, clinically diagnosed cases are uncommon overall, but it is still one of the most frequent reasons for vision not being as sharp as expected after surgery. Symptoms typically begin about 4–6 weeks after the operation. Many cases resolve spontaneously within a few months, but persistent or recurrent cases occur and matter. AAO JournalCollaborativeEYEEyeWiki

Pathophysiology

Cataract surgery is very safe, but it still causes a small amount of inflammation inside the eye. Inflammation triggers chemical signals called prostaglandins and other mediators. These signals loosen the “blood-retinal barrier,” which normally keeps fluid inside tiny retinal blood vessels. When the barrier leaks, fluid seeps into the macula and collects between layers of retinal cells. These little pools of fluid join to make cysts, and the macula becomes thicker. Thicker macula = blurrier vision. In long-lasting cases, the macula can also develop a thin partial hole or a small pocket of fluid under the retina. EyeWiki

Symptoms usually begin about four to six weeks after cataract surgery. The most common complaint is painless blurry central vision. Many patients improve without treatment within three to twelve months. Others have persistent or recurrent swelling and need medicine or procedures. EyeWiki+1

Types

Subclinical (imaging-only) PCME
There is swelling on scans or dye tests, but the person does not notice vision problems. Doctors often watch these cases closely because many resolve. EyeWiki
Clinical (symptomatic) PCME
There is swelling plus noticeable vision symptoms such as blur or distortion. This is what most people mean by “Irvine–Gass Syndrome.” EyeWiki
Acute PCME
Swelling appears within the first weeks after surgery. It may improve on its own or with short courses of drops. EyeWiki
Chronic or persistent PCME
Swelling lasts beyond three months or keeps returning. This type is more likely to need stronger treatment. Case reports show persistence can rarely last many months. PMC+1
Recurrent PCME
Swelling clears, then comes back later, sometimes after additional eye procedures like laser capsulotomy. EyeWiki
Traction-associated PCME
Swelling occurs together with pulling on the macula from the vitreous gel or a thin surface membrane (epiretinal membrane). These mechanical issues can sustain or worsen edema. EyeWiki
High-risk comorbidity PCME
The cataract surgery was routine, but the eye had risk-raising conditions like diabetes or prior uveitis. These eyes need closer follow-up. EyeWiki

Causes and Risk Factors

These are practical “drivers” that raise the chance of Irvine–Gass Syndrome or make it harder to clear:

Normal post-surgery inflammation – Even smooth surgery releases inflammatory chemicals that can leak fluid into the macula. EyeWiki
Posterior capsule rupture – A tear in the thin lens capsule increases inflammation and vitreous disturbance. EyeWiki
Vitreous loss into the wound – Vitreous prolapse can tug on the macula and fuel swelling. EyeWiki
Iris trauma or heavy manipulation – Extra handling raises inflammatory signals. EyeWiki
Retained lens fragments or later vitrectomy for lens pieces – These keep inflammation going. EyeWiki
Dislocated or malpositioned intraocular lens – An IOL that rubs or sits abnormally can irritate tissues. EyeWiki
Early Nd:YAG laser capsulotomy – A very early laser opening of the capsule may trigger or unmask edema in some eyes. EyeWiki
Anterior chamber or iris-fixated IOLs – Certain lens placements can raise risk compared with standard posterior chamber IOLs. EyeWiki
Diabetes (especially with prior diabetic macular edema) – Diabetic eyes already have fragile retinal vessels, so surgery-related inflammation more easily causes leakage. EyeWiki
Pre-existing uveitis – A history of eye inflammation makes the eye more reactive after surgery. EyeWiki
Prostaglandin-analog glaucoma drops in the peri-operative period – These helpful pressure-lowering drops can, in some situations, add to prostaglandin load and have been linked to PCME in susceptible eyes. Decisions about stopping or continuing are individualized. EyeWiki
Epiretinal membrane (ERM) – A thin scar on the macula can both result from edema and worsen it by traction. EyeWiki
History of retinal vein occlusion (RVO) – These eyes have compromised retinal circulation and are more edema-prone after surgery. EyeWiki
Vitreomacular traction – The vitreous gel pulling on the fovea keeps fluid from clearing. EyeWiki
Systemic hypertension and vascular disease – Weaker capillary walls and poor perfusion can promote edema after surgical stress (not unique to PCME but contributes). Recent reviews highlight systemic comorbidities as risk multipliers. PubMed
Longer or more complex surgery – More energy, time, or instruments generally mean more inflammation. EyeWiki
Wound leakage or unstable anterior chamber post-op – Mechanical instability can aggravate inflammation and traction. EyeWiki
Pseudoexfoliation and weak zonules – These eyes can be harder to operate on and may need more iris manipulation and devices, upping inflammatory load. EyeWiki
Prior retinal surgery or vitrectomy – Altered vitreous dynamics and retinal susceptibility can raise risk. EyeWiki
Medication-related influences (for example, peri-operative niacin or chemotherapy in rare cases) – Some systemic drugs can cause or worsen macular edema; careful medication review is part of good care. (This is uncommon in pure PCME but relevant in differential assessment.) EyeWiki

Symptoms

Painless blurry central vision – Words and faces look smudged or “through fog.” This is the top complaint. EyeWiki
Metamorphopsia – Straight lines look bent or wavy. EyeWiki
A central gray spot or small blind area – A “smudge” in the center of the view. EyeWiki
Faded or washed-out colors – Color contrast drops when the macula swells.
Poor fine detail – Trouble reading small print or threading a needle.
Worse vision in dim light – The macula is less efficient when swollen.
Glare or halos – Bright lights scatter more, making night driving hard.
Slow focusing – The image “snaps” into clarity less readily.
Eyes feel normal – There is usually no pain or redness with PCME. EyeWiki
Headaches from eye strain – The brain works harder to overcome blur.
Reduced contrast sensitivity – Faces or objects blend into the background.
Difficulty with screens – Letters look fuzzy on phones or computers.
Difficulty judging distance – Fine depth cues fade when central detail is weak.
One eye feels “weaker” than the other – If only one eye is affected.
Symptoms often start weeks after surgery – Not on day one, which helps doctors tell it apart from immediate post-op blur. EyeWiki

Diagnostic Tests

Important note: Eye doctors tailor tests to the situation. OCT and a dilated exam are the mainstays. Fluorescein angiography is used when needed. Many other tests below are supportive or used in special cases.

A) Physical exam and observation (at the slit lamp or with simple tools)

Best-corrected visual acuity
You read a chart to measure how much vision dropped. A change from your usual after cataract surgery raises suspicion for PCME.
Amsler grid at near
You look at a grid of lines. Wavy or missing lines suggest macular distortion.
Confrontation visual fields
This is a quick check for central scotomas or blind spots.
Color vision plates
Macular swelling often reduces color discrimination, especially for fine shades.
Photostress recovery test
Your macula is briefly “bleached” with light; delayed recovery points to macular dysfunction, supporting the diagnosis when scans are borderline.
Pupil testing
A relative afferent pupillary defect would suggest another problem (like optic nerve disease), helping with the differential.
Intraocular pressure measurement
Pressure is checked because pressure spikes or drops can influence vision and because steroid treatment decisions may depend on baseline pressure.
Dilated fundus exam (ophthalmoscopy)
The doctor looks for loss of the normal foveal dip, a slightly thickened macula, subtle cysts, or rare related findings like small hemorrhages or disc swelling in chronic cases. EyeWiki
Red-free (green) light inspection
This lighting can make cystic changes and fine membranes easier to see at the slit lamp. EyeWiki
Check for traction signs
The doctor looks for clues of vitreomacular traction or an epiretinal membrane, which can maintain edema. EyeWiki

B) Manual or chairside functional tests

Pinhole test
You look through a small hole. If blur improves only a little, it suggests retinal, not optical, causes.
Near-reading performance
Reading small print is sensitive to macular function and helps track progress.
Contrast sensitivity chart (e.g., Pelli-Robson)
This checks how well you see low-contrast letters, which often worsens in macular edema.
M-Charts or similar metamorphopsia tools
These quantify the amount of “waviness,” useful for follow-up.
Preferential hyperacuity perimetry (PHP)
This simple tablet-like test can detect subtle macular distortion.

These manual tests do not replace imaging; they tell the clinician how the macula performs in daily life.

C) Laboratory and pathological context (supportive, when relevant)

Blood glucose and HbA1c
If you have diabetes or borderline sugar control, these tests help explain why edema developed or persists and guide overall care. Reviews highlight diabetes as a major systemic risk factor for post-operative macular edema. PMC
Blood pressure assessment
High blood pressure and vascular disease can contribute to retinal leakage and slower recovery. PubMed
Medication review (systemic and eye drops)
Your clinician checks for drugs linked to macular edema in rare cases (for example, some chemo agents or high-dose niacin) and confirms how glaucoma drops were used around surgery. EyeWiki

There is no routine “lab test” that diagnoses PCME. Labs are used to uncover and manage contributing conditions so the macula can heal.

D) Electrodiagnostic tests (special situations)

Multifocal electroretinography (mfERG)
This test measures electrical signals from the macula. It is rarely needed for straightforward PCME, but it can document macular dysfunction or recovery in complex cases and helps separate retinal from optic-nerve causes when the picture is unclear. (Electrodiagnostics are adjuncts, not first-line tests.) NCBI

E) Imaging tests (the core of diagnosis)

Optical coherence tomography (OCT) – the main test
OCT is a painless scan that shows cross-sections of the retina. In PCME it shows tiny cysts in the inner nuclear and outer plexiform layers and measures macular thickness to track treatment. OCT can also reveal traction or a thin surface membrane if present. EyeWiki
Fluorescein angiography (FA) – the classic dye test
A small dye injection in your arm lets the camera see retinal blood flow. PCME shows capillary leakage around the fovea in a flower-petal (“petaloid”) pattern on late frames. FA also helps rule out other causes of macular leakage. EyeWiki
OCT-Angiography (OCT-A)
This scan shows tiny blood vessels without dye. It is useful to compare PCME with diabetic macular edema and to monitor vascular changes. EyeWiki
Fundus photography
Color photos document baseline appearance and changes over time.
Fundus autofluorescence (FAF)
This noninvasive photo highlights metabolic stress in the retina and can show patterns around the edematous macula.
B-scan ultrasound (rare)
Used if the view to the retina is blocked by media opacity; not a primary tool for PCME but helpful to rule out other issues when the retina cannot be seen.

In daily practice, a careful exam plus OCT usually confirms the diagnosis, and FA is added when the doctor needs more detail or when the story is atypical. EyeWiki

Non-pharmacological treatments

These steps support healing, reduce risk, and improve day-to-day functioning. They do not replace medical drops or injections when those are needed.

Watchful waiting (observation)
Description: Close follow-up when symptoms are mild and vision is acceptable.
Purpose: Many cases settle without intervention.
Mechanism: Allows natural resolution as post-surgical inflammation fades and the blood-retinal barrier reseals. PMC
Strict postoperative follow-up with OCT
Description: Regular clinic checks using optical coherence tomography.
Purpose: Detects early or persistent swelling, guides timing of treatment or taper.
Mechanism: Objective mapping of retinal thickness and cysts to track recovery. AAO Journal
Address vitreomacular traction (VMT) if present
Description: Identify traction on OCT; refer early for procedural care if traction persists.
Purpose: Traction can maintain edema until relieved.
Mechanism: Removing mechanical pulling lets the macula re-stabilize. EyeWiki
Optimize blood sugar (for diabetes)
Description: Tight, safe glycemic control with the primary doctor.
Purpose: High glucose worsens retinal leakage and slows healing.
Mechanism: Lower inflammatory/vascular stress in retinal vessels. ScienceDirect
Control blood pressure and lipids
Description: Treat systemic vascular risks.
Purpose: Healthier capillaries leak less; reduces recurrent edema risk.
Mechanism: Stabilizes retinal microcirculation and endothelial function. ScienceDirect
Medication review and adjustment
Description: Check for drugs linked to macular edema (e.g., high-dose niacin; glaucoma prostaglandin analogs in some high-risk eyes).
Purpose: Remove possible aggravators.
Mechanism: Stopping a trigger can allow edema to clear. (Note: evidence on prostaglandin analogs is mixed; they’re not routinely stopped in uncomplicated cases.) PMC+2PMC+2Review of Optometry
Avoid early Nd:YAG capsulotomy unless necessary
Description: Delay laser for posterior capsule haze until inflammation is quiet.
Purpose: Early capsulotomy can sometimes be followed by CME.
Mechanism: Minimizes added energy/inflammation while the macula heals. American Academy of Ophthalmology
UV/blue-light protection
Description: Wear quality sunglasses outdoors.
Purpose: Lowers light-induced oxidative stress after surgery.
Mechanism: Reduces photochemical stress that can amplify inflammation. IOVS
No eye rubbing; gentle eyelid hygiene
Description: Keep lids/lashes clean; avoid pressure on the eye.
Purpose: Reduces surface inflammation and mechanical stress.
Mechanism: Limits cytokine “spillover” from surface to the interior.
Follow all post-op activity restrictions
Description: Avoid heavy lifting/straining early after surgery.
Purpose: Prevents pressure surges and inflammation spikes.
Mechanism: Less Valsalva-related vascular leakage.
Treat ocular surface dryness/blepharitis
Description: Warm compresses, lid cleaning, preservative-free tears.
Purpose: Quieter surface → fewer inflammatory mediators entering the eye.
Mechanism: Reduces prostaglandin/cytokine load from the ocular surface. Review of Ophthalmology
Home Amsler grid monitoring
Description: Daily self-check for waviness or new blind spots.
Purpose: Encourages early reporting of change.
Mechanism: Quick detection of progression that needs urgent care.
Low-vision aids (temporary)
Description: Proper lighting, magnifiers, large-print devices.
Purpose: Improves quality of life while the macula settles.
Mechanism: Compensates for reduced contrast and central blur.
Anti-glare and high-contrast habits
Description: Adjust screen contrast, use anti-glare lenses.
Purpose: Reduces symptom burden from metamorphopsia.
Mechanism: Makes reading/near tasks easier during recovery.
Healthy sleep and posture
Description: Regular sleep; avoid face-down/pressure on the eye.
Purpose: Support overall healing; avoid nocturnal pressure elevations.
Mechanism: Autonomic balance and ocular perfusion stability.
Stop smoking and limit alcohol
Description: Lifestyle change.
Purpose: Smoking worsens retinal microvascular health; alcohol can raise inflammation.
Mechanism: Improves endothelial function and oxygen delivery. PubMed
Cardiorespiratory fitness (moderate exercise)
Description: 150 minutes/week, as cleared by your doctor.
Purpose: Lowers systemic inflammation; supports vascular health.
Mechanism: Improves nitric-oxide-mediated vascular tone.
Dietary pattern: Mediterranean-style
Description: Vegetables, fruits, legumes, fish, nuts, whole grains; low ultra-processed foods.
Purpose: Nutrient pattern tied to healthier macula in other retinal diseases.
Mechanism: Antioxidant and anti-inflammatory nutrients support retinal cells. National Institutes of Health (NIH)
Educate on realistic recovery timelines
Description: Understand that improvement can be gradual.
Purpose: Encourages adherence to visits and drops.
Mechanism: Better adherence → better outcomes. AAO Journal
Prompt care for new floaters/flashes/pain
Description: Don’t wait if symptoms change suddenly.
Purpose: Rules out other causes (e.g., retinal tear, high pressure).
Mechanism: Early detection prevents complications.

Drug treatments

Dosing here reflects common clinical use; your ophthalmologist will individualize your regimen. Many uses are off-label specifically for Irvine–Gass.

Nepafenac (0.1% TID or 0.3% once daily) — topical NSAID
Timing: Weeks to a few months, then taper.
Purpose/Mechanism: Blocks COX enzymes → lowers prostaglandins → reduces macular leakage.
Side effects: Stinging; rare corneal issues in compromised corneas. Strong evidence supports NSAIDs for prevention and treatment of pseudophakic CME. PubMedNature
Bromfenac (0.07% once daily or 0.09% daily–BID) — topical NSAID
Timing: Similar to nepafenac.
Purpose/Mechanism: Potent COX-2 inhibition; good tissue penetration.
Side effects: Irritation; rare corneal complications. PubMed
Ketorolac (0.4–0.5% QID) — topical NSAID
Timing: Weeks, then taper.
Purpose/Mechanism: COX inhibition → anti-inflammatory.
Side effects: Burning; rare epithelial problems. (Classic trial compared NSAID vs steroid vs combo.) EyeWiki
Prednisolone acetate 1% (QID then taper) — topical corticosteroid
Timing: Weeks to months, guided by OCT.
Purpose/Mechanism: Broad anti-inflammatory (genomic and non-genomic); stabilizes blood-retinal barrier.
Side effects: Eye-pressure rise, infection risk; monitor IOP.
Difluprednate 0.05% (QID → taper) — topical corticosteroid
Timing: Often used when edema is more stubborn.
Purpose/Mechanism: High-potency steroid reduces cytokine cascade.
Side effects: Higher IOP-spike risk; careful follow-up needed.
Sub-Tenon (posterior) triamcinolone acetonide (≈40 mg) — periocular steroid injection
Timing: Single injection; effects last weeks to months.
Purpose/Mechanism: Depot steroid diffuses to macula; strong anti-inflammatory action.
Side effects: IOP rise, rare ptosis/infection. EyeWiki
Intravitreal triamcinolone acetonide (1–4 mg) — intravitreal steroid
Timing: One injection; may repeat if needed.
Purpose/Mechanism: High local steroid level reduces leakage.
Side effects: IOP spikes, floaters, rare endophthalmitis; off-label for PCME. EyeWiki
Dexamethasone 0.7-mg intravitreal implant (Ozurdex®) — sustained steroid
Timing: Works ~3–4 months; can be repeated.
Purpose/Mechanism: Long-acting anti-inflammatory to dry persistent CME; evidence includes subgroup analyses and series in pseudophakic CME.
Side effects: IOP rise; rare infection. (FDA-approved for other macular edemas; used off-label in IGS.) PMCPubMedSpandidos Publications
Anti-VEGF injections — bevacizumab 1.25 mg / ranibizumab 0.5 mg / aflibercept 2 mg
Timing: Often monthly for 1–3 doses, then reassess.
Purpose/Mechanism: Lowers vascular permeability by blocking VEGF; helpful in some refractory cases.
Side effects: Rare infection, pressure spikes. (Evidence supports benefit; cost-effectiveness often favors bevacizumab.) PMC+1
Acetazolamide (250 mg oral, BID–TID, short course) — carbonic anhydrase inhibitor
Timing: 1–4 weeks, if tolerated.
Purpose/Mechanism: Improves retinal pigment epithelium (RPE) fluid pumping to move fluid out of the retina; widely used for inflammatory CME and sometimes PCME.
Side effects: Tingling, fatigue, kidney stones, sulfur allergy cross-reactivity; rare choroidal effusions have been reported. PMCScienceDirectMDPI

Dietary molecular supplements

Supplements can support retinal health; none is a proven cure for Irvine–Gass. Discuss with your doctor, especially if you take blood thinners or have kidney stones.

Lutein 10 mg + Zeaxanthin 2 mg daily
Function: Enriches macular pigment; filters blue light; antioxidant support.
Mechanism: Carotenoids concentrate in macula and neutralize free radicals. (AREDS2 supports lutein/zeaxanthin for AMD risk—extrapolated for macular support.) National Eye InstituteNational Institutes of Health (NIH)
Omega-3s (EPA+DHA ≈ 1,000 mg/day)
Function: Anti-inflammatory membrane lipids; vascular health.
Mechanism: Compete with arachidonic acid pathways, modulating prostaglandins/leukotrienes. PubMedPMC
Vitamin C (≈500 mg/day)
Function: Water-soluble antioxidant cofactor.
Mechanism: Scavenges reactive oxygen species; supports collagen in capillaries. (Included in AREDS-style antioxidant patterns.) University of Michigan Health
Vitamin E (≤400 IU/day)
Function: Lipid-phase antioxidant.
Mechanism: Protects cell membranes from peroxidation. (Use prudently; not for everyone.) University of Michigan Health
Zinc (25–40 mg elemental/day) with Copper (2 mg/day)
Function: Antioxidant enzyme cofactor; immune support.
Mechanism: Stabilizes retinal metabolism and antioxidant enzymes. (Paired with copper to avoid deficiency.) National Eye Institute
Curcumin (500–1,000 mg/day with piperine for absorption)
Function: Anti-inflammatory and antioxidant botanical.
Mechanism: Down-regulates NF-κB, COX-2, and inflammatory cytokines; retinal benefits shown in preclinical/early studies. PMC+1
N-acetylcysteine (NAC) (600 mg 1–2×/day)
Function: Glutathione precursor; antioxidant.
Mechanism: Repletes intracellular GSH; protects RPE and neural retina from oxidative stress (preclinical and early translational evidence). PMCNature
Resveratrol (150–250 mg/day)
Function: Polyphenol with antioxidant/vasoprotective effects.
Mechanism: Activates antioxidant pathways; modulates endothelial function. (Human retinal data limited.)
Quercetin (≈500 mg/day)
Function: Flavonoid with anti-inflammatory actions.
Mechanism: Inhibits pro-inflammatory enzymes and cytokines; antioxidant support. (Evidence largely preclinical.)
Bilberry/anthocyanins (80–160 mg extract/day)
Function: Antioxidant pigments supporting microcirculation.
Mechanism: May improve capillary integrity and reduce oxidative stress. (Clinical evidence modest.)

Note: AREDS2-type formulas are proven for AMD, not specifically for Irvine–Gass; they are listed here as supportive background nutrition for retinal health. National Institutes of Health (NIH)

Regenerative / stem-cell” options

There are no approved stem-cell drugs for Irvine–Gass syndrome. The items below explain what’s actually used (immune-modulating) and what remains experimental.

Corticosteroids (topical, periocular, intravitreal)
Dosage: See steroid items above.
Function: Potent local immunomodulation to quiet postoperative inflammation.
Mechanism: Inhibits multiple inflammatory genes; restores blood-retinal barrier. Strong real-world evidence in IGS. EyeWiki
Dexamethasone intravitreal implant (0.7 mg)
Dosage: Single implant, repeat PRN at ~3–4 months.
Function: Long-acting local immunomodulation for persistent CME.
Mechanism: Sustained steroid delivery to the macula. (Off-label for IGS, supported by clinical studies/series.) PMCPubMed
Anti-VEGF injections
Dosage: Bevacizumab 1.25 mg / Ranibizumab 0.5 mg / Aflibercept 2 mg, usually monthly initially.
Function: “Vascular normalization” to shrink leakage.
Mechanism: VEGF blockade decreases permeability. (Off-label for PCME; evidence supports benefit in selected cases.) PMC+1
Interferon-α (topical or systemic in refractory cases, off-label)
Dosage: Varies widely in case reports.
Function: Immunomodulator for stubborn inflammation.
Mechanism: Alters cytokine signaling; small case series report success in chronic PCME. Use only under subspecialist care. EyeWiki
Other immunomodulators (rare/off-label: e.g., methotrexate/sirolimus intravitreal in selected inflammatory CME)
Dosage: Specialist protocols only.
Function: Suppress intraocular inflammatory signaling when steroids are not tolerated.
Mechanism: Anti-proliferative or mTOR-mediated cytokine reduction. (Evidence in PCME is limited; reserve for expert centers.) Wikipedia
Stem-cell or regenerative cell therapy — experimental only
Dosage: No approved product for IGS.
Function/Mechanism: Proposed retinal support or barrier repair.
Status/Caution: Use only in clinical trials; not standard care for IGS. (No proven benefit; risks can be serious.)

Surgeries

Pars plana vitrectomy (PPV)
Procedure: Micro-incision removal of vitreous gel; often with removal of traction and inflammatory debris.
Why: For refractory CME or when vitreomacular traction is present. Many series show edema improvement and vision gains in suitable cases. PubMedEyeWiki
PPV with membrane/ILM peel (when ERM/VMT present)
Procedure: Peeling of epiretinal membrane and/or internal limiting membrane during PPV.
Why: Releases subtle traction that maintains edema. PubMedAjo
Removal of retained lens fragments (when present)
Procedure: Surgical cleanup of lens material left behind after cataract surgery.
Why: Retained fragments drive persistent inflammation and CME; removing them treats the cause. ophed.com
Intraocular lens (IOL) reposition or exchange for UGH/malposition
Procedure: Move or replace a lens that rubs the iris (UGH syndrome) or sits incorrectly.
Why: Mechanical chafing causes inflammation and CME; fixing the IOL often resolves the problem. EyeWikiKarger
Deferred Nd:YAG capsulotomy (when PCO truly limits vision)
Procedure: Laser opening of cloudy posterior capsule months after surgery.
Why: Improves clarity once inflammation is controlled. (Early YAG can be followed by CME in a small percentage; timing matters.) American Academy of Ophthalmology

Preventions

Risk-stratified planning for patients with diabetes, uveitis, retinal vein disease, or prior CME. ScienceDirect
Pre-/post-op topical NSAIDs, often combined with a steroid, lower CME risk. PubMedPMCCRSToday
Meticulous surgical technique (shorter time, smaller incisions, minimal iris/vitreous trauma). Review of Ophthalmology
Manage vitreous loss and lens fragments promptly when they occur. ophed.com
Optimize glucose and blood pressure before and after surgery. ScienceDirect
Judicious use of prostaglandin-analog glaucoma drops in high-risk eyes (evidence mixed; do not stop automatically—discuss with surgeon). Review of OptometryPMC
Delay Nd:YAG capsulotomy until the eye is quiet and the macula is stable. American Academy of Ophthalmology
Limit operating microscope light and energy exposure to what’s necessary. Review of Optometry
Avoid high-dose niacin unless essential; monitor promptly if it’s used for cholesterol. PMC
Educate patients to report blurred central vision or distortion 4–8 weeks after surgery. CollaborativeEYE

When to see a doctor (or go urgently)

Sudden central blur, straight lines look wavy, or a new dark spot—especially within 1–2 months after cataract surgery. CollaborativeEYE
New floaters/flashes or a curtain over vision (possible retinal tear/detachment).
Eye pain, redness, or light sensitivity (possible inflammation/infection).
Headache, halos, or nausea with eye discomfort (possible pressure spike from steroid response).
No improvement or worsening after starting treatment.

Foods to favor — and to limit/avoid

Eat more of (most days):

Dark leafy greens (spinach, kale) — lutein/zeaxanthin for macular pigment. National Eye Institute
Colored vegetables & fruits (peppers, oranges, berries) — antioxidants.
Fatty fish (salmon, sardines, hilsa) 2–3×/week — omega-3s for retinal membranes. PubMed
Legumes (lentils, chickpeas) — vascular-friendly fiber.
Nuts and seeds (walnut, almond, flax) — healthy fats.
Olive oil — anti-inflammatory monounsaturated fats.
Whole grains — steadier glucose control.
Eggs — natural lutein/zeaxanthin.
Citrus & kiwi — vitamin C.
Plenty of water — general eye comfort.

Limit/avoid:

High-dose niacin supplements unless medically essential. PMC
Trans fats/ultra-processed snacks — pro-inflammatory.
Sugary drinks — glucose spikes stress retinal vessels.
Excess alcohol — raises inflammation.
Heavy salt — can worsen vascular strain.
Deep-fried foods — oxidized oils.
Excessive red/processed meats — swap for fish/legumes more often.
Empty-calorie desserts — crowd out nutrient-dense foods.
Large caffeine surges right before eye-pressure checks.
Any supplement not cleared with your doctor (interactions/side effects).

Frequently asked questions

Will my vision go back to normal?
Often yes. Many cases improve within weeks to months; persistent cases usually respond to drops, injections, or (rarely) surgery. PMC
When does Irvine–Gass usually start?
Commonly 4–6 weeks after cataract surgery, but it can appear earlier or later. CollaborativeEYE
How is it diagnosed?
With an eye exam and OCT scan that shows macular swelling; sometimes a fluorescein angiogram is used. AAO Journal
Do I always need treatment?
Not always. Mild cases can be watched; treatment starts if vision is affected or swelling persists. PMC
Are NSAID drops really helpful?
Yes—high-quality evidence shows topical NSAIDs help prevent and treat pseudophakic CME; combinations with steroids are common. PubMedNature
What about steroid drops or injections?
They’re a cornerstone when inflammation drives the problem; options range from drops to periocular/intravitreal steroids or a dexamethasone implant for persistent cases. PMC
Are anti-VEGF shots used?
Yes, in some stubborn cases; they reduce vessel leakiness. Evidence supports benefit, but use is off-label for IGS. PMC+1
Is acetazolamide helpful?
It can help some patients by enhancing fluid pumping across the RPE, especially in inflammatory CME; discuss side effects and suitability. PMC
Do glaucoma prostaglandin drops cause CME?
The link is controversial. In routine, low-risk eyes they often do not need to be stopped; in higher-risk or active CME, your surgeon may adjust therapy. Review of OptometryPMC
Can a laser for capsule haze (YAG) make CME worse?
CME can occur after capsulotomy in a small percentage; timing the laser after inflammation settles helps lower risk. American Academy of Ophthalmology
When do you consider surgery?
If medicine fails or if traction or a lens problem is driving the edema—then vitrectomy or IOL surgery may be recommended. PubMedEyeWiki
Are stem-cell treatments available?
Not for Irvine–Gass. Any such therapy should be in clinical trials only.
How long do steroid implants last?
The dexamethasone implant typically lasts about 3–4 months; repeat dosing is sometimes needed. PMC
What if I’m diabetic?
You’re at higher risk for CME; tight glucose and blood-pressure control plus preventive drops can reduce risk and help recovery. ScienceDirect
What can I do at home right now?
Use drops exactly as prescribed, wear sunglasses outdoors, avoid eye rubbing, monitor with an Amsler grid, eat a Mediterranean-style diet, and call promptly for any sudden change. National Institutes of Health (NIH)

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.